Capital Access Group

Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.

Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.

Colin Smith
  • Colin Smith

Personal Group | FY25 results – A brilliant year of progress

Personal Group has delivered an excellent set of results for 2025, as presaged in the trading statement. Double-digit revenue growth translated into a 32% YoY increase in EPS to 23.3p and the dividend increased by 41% to 23.3p, in line with the growth in earnings and the new 100% payout policy. The strength of revenue growth in the core insurance business was especially notable, and the company delivered higher growth on all key metrics than peers. We make minimal changes to our forecasts for 20...

Sarah Godfrey
  • Sarah Godfrey

Social Housing REIT (SOHO) | No places like HOME

The supported housing investment sector took a significant reputational hit as a result of the failure of Home REIT (HOME). HOME has been suspended from trading for more than three years and is now in managed wind-down, offering little hope of any meaningful value recovery for its large base of both professional and individual investors. But while this debacle has undoubtedly been painful for all concerned (not least the vulnerable occupiers of HOME's ostensibly ‘modern, high-quality accommodati...

Colin Smith
  • Colin Smith

TheraCryf | Ox-1 Imminent start of final toxicology study

TheraCryf has now completed the preclinical dose range finding studies for its Orexin-1 (Ox-1) blocker lead asset. That clears the way for the imminent start of the 28-day toxicology study which is the final major preclinical study prior to submission for regulatory approval in human clinical trials. TheraCryf is on track to complete all animal studies in 3Q26 and be ready to commence clinical trials in humans by the end of 2026, a key value inflection point, for which the company is fully funde...

Colin Smith
  • Colin Smith

Personal Group | Initiation: Performing well by doing well

Personal Group combines a UK targeted affordable insurance business operating a unique business model together with a mainly SaaS based Benefits & Rewards business. The re-focused group has ambitious growth aspirations through 2030 targeting revenue of over £100m and generating EBITDA of £30m. Personal Group is growing rapidly with increasing profitability and is now committed to a 100% dividend payout policy. We forecast revenue to hit £55m by 2026 with net profit up 24% to £8.1m and an increas...

Sarah Godfrey
  • Sarah Godfrey

Foresight Environmental Infrastructure (FGEN) | Diversification boosts...

Renewable energy infrastructure funds have had a torrid few years given rising interest rates and inflation, higher discount rates and a fractious political and economic environment. FGEN was arguably already better placed than many given its diversified portfolio – with no offshore wind and a higher volume of baseload power, meaning far less intermittency or storage concerns than a pure wind or solar fund. Its moves into more esoteric growth assets may have raised eyebrows, but with constructio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch